These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 34906272)

  • 21. Nanovaccines: Merits, and diverse roles in boosting antitumor immune responses.
    Yin Q; Wang Y; Xiang Y; Xu F
    Hum Vaccin Immunother; 2022 Nov; 18(6):2119020. PubMed ID: 36170662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Engineering ApoE3-incorporated biomimetic nanoparticle for efficient vaccine delivery to dendritic cells via macropinocytosis to enhance cancer immunotherapy.
    Zhou S; Huang Y; Chen Y; Liu S; Xu M; Jiang T; Song Q; Jiang G; Gu X; Gao X; Chen J
    Biomaterials; 2020 Mar; 235():119795. PubMed ID: 32014739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic Vaccines for Cancer Immunotherapy.
    Wang J; Mamuti M; Wang H
    ACS Biomater Sci Eng; 2020 Nov; 6(11):6036-6052. PubMed ID: 33449675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nanovaccines with cell-derived components for cancer immunotherapy.
    Meng Z; Zhang Y; Zhou X; Ji J; Liu Z
    Adv Drug Deliv Rev; 2022 Mar; 182():114107. PubMed ID: 34995678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ferroptosis and Necroptosis Produced Autologous Tumor Cell Lysates Co-Delivering with Combined Immnoadjuvants as Personalized
    Shi W; Feng W; Li S; Cui Y; Liu S; Jiang H; Liu Y; Zhang H
    ACS Nano; 2023 Aug; 17(15):14475-14493. PubMed ID: 37466500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CpG-Based Nanovaccines for Cancer Immunotherapy.
    Chen W; Jiang M; Yu W; Xu Z; Liu X; Jia Q; Guan X; Zhang W
    Int J Nanomedicine; 2021; 16():5281-5299. PubMed ID: 34385817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced Antitumor Immune Responses via a Self-Assembled Carrier-Free Nanovaccine.
    Liu D; Deng B; Liu Z; Ma B; Leng X; Kong D; Ji T; Liu L
    Nano Lett; 2021 May; 21(9):3965-3973. PubMed ID: 33886338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccine-like nanomedicine for cancer immunotherapy.
    Yi Y; Yu M; Li W; Zhu D; Mei L; Ou M
    J Control Release; 2023 Mar; 355():760-778. PubMed ID: 36822241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aptamer-Functionalized Nanovaccines: Targeting
    Zheng L; Wu H; Wen N; Zhang Y; Wang Z; Peng X; Tan Y; Qiu L; Qu F; Tan W
    ACS Appl Mater Interfaces; 2023 Apr; 15(15):18590-18597. PubMed ID: 37017594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dendritic cell-based nanovaccines for cancer immunotherapy.
    Paulis LE; Mandal S; Kreutz M; Figdor CG
    Curr Opin Immunol; 2013 Jun; 25(3):389-95. PubMed ID: 23571027
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanovaccine-based strategies for lymph node targeted delivery and imaging in tumor immunotherapy.
    He A; Li X; Dai Z; Li Q; Zhang Y; Ding M; Wen ZF; Mou Y; Dong H
    J Nanobiotechnology; 2023 Jul; 21(1):236. PubMed ID: 37482608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Self-Adjuvanting Polyguanidine Nanovaccines for Cancer Immunotherapy.
    Zhang X; Wang K; Zhao Z; Shan X; Wang Y; Feng Z; Li B; Luo C; Chen X; Sun J
    ACS Nano; 2024 Mar; 18(9):7136-7147. PubMed ID: 38407021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficient Nanovaccine Delivery in Cancer Immunotherapy.
    Zhu G; Zhang F; Ni Q; Niu G; Chen X
    ACS Nano; 2017 Mar; 11(3):2387-2392. PubMed ID: 28277646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fused Cytomembrane-Camouflaged Nanoparticles for Tumor-Specific Immunotherapy.
    Ji P; Deng XC; Jin XK; Zhang SM; Wang JW; Feng J; Chen WH; Zhang XZ
    Adv Healthc Mater; 2023 Sep; 12(23):e2300323. PubMed ID: 37212324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nanovaccines for cancer immunotherapy.
    Zhang Y; Lin S; Wang XY; Zhu G
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Sep; 11(5):e1559. PubMed ID: 31172659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent progress of dendritic cell-derived exosomes (Dex) as an anti-cancer nanovaccine.
    Xia J; Miao Y; Wang X; Huang X; Dai J
    Biomed Pharmacother; 2022 Aug; 152():113250. PubMed ID: 35700679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endolysosomal-Escape Nanovaccines through Adjuvant-Induced Tumor Antigen Assembly for Enhanced Effector CD8
    Qiu L; Valente M; Dolen Y; Jäger E; Beest MT; Zheng L; Figdor CG; Verdoes M
    Small; 2018 Apr; 14(15):e1703539. PubMed ID: 29493121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor cell-based vaccine: an effective strategy for eradication of cancer cells.
    Sadeghi Najafabadi SA; Bolhassani A; Aghasadeghi MR
    Immunotherapy; 2022 Jun; 14(8):639-654. PubMed ID: 35481358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer immunotherapy: moving forward with peptide T cell vaccines.
    Kumai T; Fan A; Harabuchi Y; Celis E
    Curr Opin Immunol; 2017 Aug; 47():57-63. PubMed ID: 28734176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent Advances of Emerging Spleen-Targeting Nanovaccines for Immunotherapy.
    He X; Wang J; Tang Y; Chiang ST; Han T; Chen Q; Qian C; Shen X; Li R; Ai X
    Adv Healthc Mater; 2023 Sep; 12(23):e2300351. PubMed ID: 37289567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.